We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEO icon
76
NeoGenomics
NEO
$1.9B
$6.67M 0.15%
913,082
-303,674
-25% -$2.45M
WAY
77
Waystar Holding Corp
WAY
$4.27B
$6.16M 0.14%
150,610
+6,184
+4% +$238K
AXSM icon
78
Axsome Therapeutics
AXSM
$11.8B
$5.87M 0.13%
56,253
-40,154
-42% -$4.25M
GKOS icon
79
Glaukos
GKOS
$9.21B
$5.78M 0.13%
55,926
– –
GILD icon
80
Gilead Sciences
GILD
$167B
$5.7M 0.13%
51,416
-3,606
-7% -$384K
IQV icon
81
IQVIA
IQV
$34.4B
$5.31M 0.12%
33,700
-27,368
-45% -$4.12M
ASND icon
82
Ascendis Pharma A/S
ASND
$17.1B
$4.95M 0.11%
28,655
+26,755
+1,408% +$4.36M
BAX icon
83
Baxter International
BAX
$11.7B
$4.61M 0.1%
152,291
-304,155
-67% -$9.22M
OMDA
84
Omada Health Inc
OMDA
$1.41B
$4.58M 0.1%
+250,000
New +$4.33M
BTSG icon
85
BrightSpring Health Services
BTSG
$13.9B
$4.52M 0.1%
191,706
-50,043
-21% -$1.04M
TXG icon
86
10x Genomics
TXG
$5.55B
$3.78M 0.08%
326,751
+95,754
+41% +$873K
BNTX icon
87
BioNTech
BNTX
$23.1B
$3.73M 0.08%
35,039
+27,075
+340% +$2.73M
CAH icon
88
Cardinal Health
CAH
$53.5B
$3.36M 0.07%
20,012
-764
-4% -$113K
LEGN icon
89
Legend Biotech
LEGN
$4.31B
$3.03M 0.07%
85,438
-5,753
-6% -$186K
AZN icon
90
AstraZeneca
AZN
$262B
$2.68M 0.06%
19,200
-800
-4% -$112K
ILMN icon
91
Illumina
ILMN
$28.2B
$2.64M 0.06%
27,624
– –
COR icon
92
Cencora
COR
$59.9B
$2.39M 0.05%
7,970
-63,390
-89% -$18.3M
MRK icon
93
Merck
MRK
$315B
$2.24M 0.05%
28,239
-203,132
-88% -$16.1M
KMTS
94
Kestra Medical Technologies
KMTS
$1.43B
$2.22M 0.05%
133,761
– –
CVS icon
95
CVS Health
CVS
$137B
$2.08M 0.05%
30,096
-1,659
-5% -$109K
SPY icon
96
State Street SPDR S&P 500 ETF Trust
SPY
$782B
$1.92M 0.04%
3,100
-2,560
-45% -$1.46M
BMY icon
97
Bristol-Myers Squibb
BMY
$124B
$1.72M 0.04%
37,177
+11,611
+45% +$570K
PFE icon
98
Pfizer
PFE
$143B
$1.72M 0.04%
70,915
-49,831
-41% -$1.16M
VRNA
99
DELISTED
Verona Pharma
VRNA
$1.51M 0.03%
15,927
-45,334
-74% -$3.36M
DOCS icon
100
Doximity
DOCS
$3.87B
$1.46M 0.03%
23,816
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.